# NCT05561387 (NCT05561387)

> Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05561387
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Plasma Cell Myeloma
- Interventions: Bortezomib; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 510
- Primary outcome: Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2
- Primary outcome: Overall survival (OS) of Arm 1 vs. Arm 3

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05561387